First Medical Patent Issued for the Oculenz(TM) Augmented Reality Glasses
Ocutrx(TM) AR Glasses Garners First Medical Patent for Restoring Functional Sight to Patients with Visual Field Deficits
IRVINE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California based Augmented Reality (AR) Glasses developer today announced that the company's core AR medical application technology has been issued its first patent by the United States Patent and Trademark Office (USPTO). The company's Augmented Reality headset, called Oculenz(TM) boasts the widest field-of-vision in the industry, with a 110-degree high-resolution heads-up display, in a wirelessly connected, untethered, micro-weight headset. The patent also teaches how the Oculenz ARwear(TM) can work in conjunction with smart contact lenses as the display and eye-tracking.
"This first patent award validates our core technology for using our AR platform innovations for medical applications," stated Michael H. Freeman, CEO/CTO and Founder of Ocutrx. "This is a real milestone for creating value for Ocutrx's patent portfolio and an incredible step forward in securing patent rights around the world," Freeman said. "We immediately filed a Continuation Patent to focus on the previously filed specification elements incorporating eye-tracking with an AR head mounted display for the larger AR market."
The company plans to also market their Oculenz to other sectors including gaming, commercial, industrial, HAZMAT, e-commerce, aerospace, drones and defense. "While many AR companies built a platform first, and are now looking to find a market," said Scott Evans, M.B.A., Ocutrx COO, "we strategically designed our first ARwear for the medical industry, where there are many highly-motivated buyers, then we intent to expand into the AR market-at-large."
Ocutrx was founded in 2015 by Michael H. Freeman, an Emmy Award-winning designer of streaming mobile video technology which became the basis for the IEEE 802.11(n) MIMO standard. Freeman created the first streaming smart-phone video product which was licensed by virtually all of the cell companies which existed in the 1990's. The streaming video technology and patents were later sold to Samsung Electronics.
"The Oculenz is the first ground-breaking technology to offer a solution for advanced central visual defects in patients with retinal disease," said Dr. Thomas Finley, M.D. a Vitreoretinal surgeon and member of the Ocutrx International Medical Advisory Board (IMAB). "This innovative AR device brings a new hope to regain functional vision previously considered impossible. The impact on the individual's quality of life and retained or regained ability to productively function at home and in the workplace will be immeasurable."
The USPTO determined that Ocutrx's first patent application was allowable covering a diagnostic phase where the patients can wear the Oculenz to map their own retinal defects, alone or with the help of their physicians, and a second corresponding display phase where the video is buffered according to the retinal map and displayed over the patient's real-world vision. The Oculenz's buffered display shows all the real-world video image, but none is shown on the exact area of the patient's eye defect. Instead, it is directed to the patient's existing good areas of the macula or near adjacent peripheral retina.
"The Oculenz technology works somewhat like how we all have a natural blind spot in our vision that we do not realize on a day to day basis," said Dr. Lars Freisberg, M.D., an international Retinal Specialist surgeon, licensed in the U.S., Norway and Germany, and member of the Ocutrx IMAB. "However, you never really see this hole," explained Dr. Freisberg, "because the brain fills it in with other gathered visual information."
"With the Oculenz the idea is that the patient senses the entire image and learns to disregard the defect area through 'neural adaptation' due to the 'plasticity of the brain,'" said Dr. R. Wade Crow, M.D., Neural Ophthalmologist and Assistant Professor of Neuro-Ophthalmology at the University of California-Irvine and member of the Ocutrx IMAB. "Working with visual input, the brain can train itself to not see redundant or unnecessary things."
About Ocutr x
With corporate headquarters in the OC at Irvine, California, and a research and R&D lab in the Midwest, located in Oklahoma, Ocutrx is a new breed of AR manufacturing company focusing on the lightest weight headset with the largest field-of-vision in the market. At a time when worldwide applications for easy-to-wear and easy-to-use AR solutions are being touted as the "next big thing after the smartphone" Ocutrx is creating impactful, revolutionary "AR glasses for the masses"(TM).
To learn more about Ocutrx, please visit the company website at www.ocutrxarwear.com.
Ocutrx Vision Technologies, LLC
Photos accompanying this announcement are available at
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ocutrx Vision Technologies, LLC via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
WillScot Announces Closing of Warrant Exchange Offer11.12.2018 22:05 | Pressemelding
BALTIMORE, Dec. 11, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced the closing of its previously announced exchange offer (the “Exchange Offer”) relating to certain outstanding warrants issued in 2015 (the “Warrants”). Under the terms of the Exchange Offer, each Warrant holder had the opportunity to receive 0.18182 shares of WillScot Class A Common Stock, par value $0.0001 per share (“Common Stock”), for each Warrant tendered by the holder and exchanged pursuant to the Exchange Offer. As of the closing of the Exchange Offer on December 11, 2018, 45,131,827 outstanding Warrants were properly tendered and not withdrawn in the Exchange Offer. 45,031,827 of the Warrants tendered were public warrants, representing approximately 89% of the public warrants, and approximately 100,000 Warrants tendered were private warrant
DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02 | Pressemelding
Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00 | Pressemelding
Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach
INN Launches Battery Metals Channel11.12.2018 15:00 | Pressemelding
The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30 | Pressemelding
KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix
Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00 | Pressemelding
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom